Sarah Lyons
Head of Privacy Analytics
Menu
Beyond Data Transparency: Innovation Across the Drug Development Lifecycle
Beyond Data Transparency: Innovation Across the Drug Development Lifecycle
Once a drug company has clinical trial transparency (CTT) capabilities in place, new opportunities to drive value further along the drug development life cycle also emerge.
In this presentation, General Manager Sarah Lyons discusses how risk-based, statistical anonymization protects patient privacy while enabling insight-rich data, helping you:
If you’re looking to comply with drug authorization regulations, share insight-rich data with health researchers, or scale anonymization for internal data strategies and drug development, this presentation is for you.
Sarah helps Privacy Analytics’ clients earn trust and execute on their use priorities. Her career has often involved developing and implementing innovative risk assessment methodologies for governments and Fortune 500 companies. She has worked with decision makers at the highest level to identify and address financial, political and/or reputational risk before any harm could be done to the organization. Her previous roles include Partner and National Privacy Services Leader at MNP LLP, COO of A Hundred Answers Inc., and IT Risk Advisory Practice Lead for Ernst & Young Ottawa.
Sarah Lyons
Head of Privacy Analytics
Situation: California’s Consumer Privacy Act inspired Comcast to evolve the way in which they protect the privacy of customers who consent to share personal information with them.
Situation: Integrate.ai’s AI-powered tech helps clients improve their online experience by sharing signals about website visitor intent. They wanted to ensure privacy remained fully protected within the machine learning / AI context that produces these signals.
Situation: Novartis’ digital transformation in drug R&D drives their need to maximize value from vast stores of clinical study data for critical internal research enabled by their data42 platform.
Situation: CancerLinQ™, a subsidiary of American Society of Clinical Oncology, is a rapid learning healthcare system that helps oncologists aggregate and analyze data on cancer patients to improve care. To achieve this goal, they must de-identify patient data provided by subscribing practices across the U.S.
Situation: Needed to ensure the primary market research process was fully compliant with internal policies and regulations such as GDPR.
Situation: Needed to enable AI-driven product innovation with a defensible governance program for the safe and responsible use
of voice-to-text data under Shrems II.
This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.